
Revenues are down as the bottom line deficit at Leo Pharma grows, the company’s annual report for 2021 reveals.
The company’s negative result has increased fivefold, from a reported DKK -951m in 2020 to DKK -4.9bn in 2021 (USD 141m to USD 726.6m), whereas the top line shrinks after a number of product divestments to DKK 9.96bn from preceding period’s DKK 10.13bn (USD 1.47bn from USD 1.5bn).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app